Retatrutide + Placebo
Phase 1Active 0 watching 0 views this week💤 Quiet
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Type 2 Diabetes Mellitus
Conditions
Type 2 Diabetes Mellitus
Trial Timeline
Jun 6, 2025 → May 1, 2026
NCT ID
NCT06982846About Retatrutide + Placebo
Retatrutide + Placebo is a phase 1 stage product being developed by Eli Lilly for Type 2 Diabetes Mellitus. The current trial status is active. This product is registered under clinical trial identifier NCT06982846. Target conditions include Type 2 Diabetes Mellitus.
Hype Score Breakdown
Clinical
10
Activity
5
Company
10
Novelty
3
Community
2
Clinical Trials (12)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07232719 | Phase 3 | Recruiting |
| NCT06982846 | Phase 1 | Active |
| NCT07035093 | Phase 3 | Recruiting |
| NCT06859268 | Phase 3 | Active |
| NCT06383390 | Phase 3 | Active |
| NCT06354660 | Phase 3 | Completed |
| NCT06297603 | Phase 3 | Active |
| NCT05931367 | Phase 3 | Completed |
| NCT05936151 | Phase 2 | Completed |
| NCT05929079 | Phase 3 | Active |
| NCT05929066 | Phase 3 | Active |
| NCT05882045 | Phase 3 | Active |
Competing Products
20 competing products in Type 2 Diabetes Mellitus